Skin Cancer News and Research RSS Feed - Skin Cancer News and Research

Skin cancer is the most common type of cancer in the U.S. It occurs in more than a million people each year, including many older people. There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma, and melanoma. Of the three, melanoma is the most serious. Skin cancer occurs when abnormal cells form and multiply in an uncontrolled way in the epidermis, or abnormal cells from the epidermis invade the dermis of the skin. Basal cell carcinoma, squamous cell carcinoma, and melanoma are skin cancers that are named for the epidermal cells from which they develop.
Progenitor cells responsible for generation and maintenance of Merkel cells

Progenitor cells responsible for generation and maintenance of Merkel cells

Researchers have identified a population of "progenitor" cells in the skin that are solely responsible for the generation and maintenance of touch-sensing Merkel cells. The study appears in The Journal of Cell Biology. [More]
Researchers reveal role of epigenetic factors in malignant skin cancer

Researchers reveal role of epigenetic factors in malignant skin cancer

Melanoma, the most aggressive of all skin cancer strains, is often fatal for patients due to the pronounced formation of metastases. Until now, a melanoma's rampant growth was mainly attributed to genetic causes, such as mutations in certain genes. However, researchers from the University of Zurich now reveal that so-called epigenetic factors play a role in the formation of metastases in malignant skin cancer. This opens up new possibilities for future cancer treatments. [More]
Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals doses first actinic keratosis patient with KX2-391 ointment

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas. [More]
Women battling breast cancer to be honored at annual 'Lobos Love Pink' basketball game

Women battling breast cancer to be honored at annual 'Lobos Love Pink' basketball game

The University of New Mexico Women's Basketball team will generously pay tribute to the courageous women battling breast cancer in our state as they have year after year. Along with the support of UNM Cancer Center, UNM Hospitals and UNM Athletics, the Lady Lobos will face the University of Nevada, Reno Wolf Pack on Valentine's Day for the annual "Lobos Love Pink" basketball game for breast cancer awareness. [More]
CNIO researchers identify new mechanism that influences differentiation of keratinocytes

CNIO researchers identify new mechanism that influences differentiation of keratinocytes

The formation of human skin involves a cascade of biochemical signals, which are not well understood. However, they are very important since their failure may cause diseases, such as Atopic Dermatitis and skin cancers, which affect more than 25% of the human population. [More]
Effective health messaging varies depending on target audience

Effective health messaging varies depending on target audience

Is it better to tell people about the harms of certain health decisions or about the benefits of positive health related decisions? Studies that delve into this very question have differing results, however, a new paper just published by Cornell Food & Brand Lab in Nutrition Reviews, finds that the type of health messaging that is most effective might vary depending on certain characteristics of the target audience. [More]
Children of melanoma survivors need better sun protection, says UCLA researchers

Children of melanoma survivors need better sun protection, says UCLA researchers

In a groundbreaking new study, UCLA researchers have discovered that children of melanoma survivors are not adhering optimally to sun protection recommendations. This is concerning as sunburns are a major risk factor for melanoma, and children of survivors are at increased risk for developing the disease as adults. [More]
British Skin Foundation urges people to check their loved ones moles this Valentine’s Day

British Skin Foundation urges people to check their loved ones moles this Valentine’s Day

Valentine’s Day is fast approaching and this year the British Skin Foundation is urging people to check your loved ones moles! Whether it’s your boyfriend, girlfriend, spouse, friend or family – take the time to check for changes in moles. [More]
ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

ULB researchers uncover new mechanism involved in tumour initiation, growth in SCC

Researchers at the Université libre de Bruxelles (Belgium) report the mechanisms regulating the different functions of Twist1 controlling skin tumour initiation, cancer stem cell function and tumor progression. [More]
Luck is a key factor in cancer development

Luck is a key factor in cancer development

A statistical model that measures the proportion of cancers that develop as a result of random mutations occurring during cell division was published in Science today. [More]
Johns Hopkins scientists create statistical model to measure proportion of cancer incidence

Johns Hopkins scientists create statistical model to measure proportion of cancer incidence

Scientists from the Johns Hopkins Kimmel Cancer Center have created a statistical model that measures the proportion of cancer incidence, across many tissue types, caused mainly by random mutations that occur when stem cells divide. [More]
Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Final Phase 1 data of zoptarelin doxorubicin Phase 1/2 trial published in Clinical Cancer Research

Aeterna Zentaris Inc. today announced that an article on final data for the Phase 1 portion of the ongoing Phase 1/2 trial in prostate cancer with zoptarelin doxorubicin (formerly AEZS-108), a hybrid molecule composed of a synthetic peptide carrier and a well-known chemotherapy agent, doxorubicin, has been published in the December issue of Clinical Cancer Research. [More]
IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL). [More]
Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p). [More]
IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

IMBRUVICA demonstrates anti-tumor activity against multiple myeloma in Phase II study

New IMBRUVICA (ibrutinib) Phase II data announced here today by Pharmacyclics, Inc) during the 56th American Society of Hematology Annual Meeting suggests that IMBRUVICA demonstrates anti-tumor activity both as a single-agent and as combination therapy in heavily pre-treated patients with relapsed or relapsed/refractory multiple myeloma (MM). [More]
Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

Organovo, Yale collaborate to develop bioprinted tissues for surgical transplantation research

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, and Yale School of Medicine, Department of Surgery have formed a collaboration to develop bioprinted tissues for surgical transplantation research, made possible by a generous gift from the Methuselah Foundation. [More]
Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects. [More]
Scientists use TPF-SHG microscopy to study effects of micro-ablative fractional laser resurfacing

Scientists use TPF-SHG microscopy to study effects of micro-ablative fractional laser resurfacing

Many people in the Western World consider it as a social need to hide the effects of aging. For this purpose, different cutaneous rejuvenation treatments have been developed, including a laser-based technique, known as laser resurfacing. [More]
Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

Study identifies genetic alterations that contribute to growth and recurrence of Ewing sarcoma

An international collaboration has identified frequent mutations in two genes that often occur together in Ewing sarcoma (EWS) and that define a subtype of the cancer associated with reduced survival. [More]
Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

Breakthrough study shows novel molecular imaging drug to detect early prostate cancer

A novel study demonstrates the potential of a novel molecular imaging drug to detect and visualize early prostate cancer in soft tissue, lymph nodes and bone. The research, published in the November issue of the Journal of Nuclear Medicine, compares the biodistribution and tumor uptake kinetics of two Tc-99m labeled ligands, MIP-1404 and MIP-1405, used with SPECT and planar imaging. [More]